Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Optomed

Viimeisimmät raportit

Laaja raportti

Analyytikko

Juha Kinnunen

Juha Kinnunen

Osakestrategi, analyytikko

Lisätiedot

Yhtiön vuosikertomukset

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
23.8.
2022

Redeye still regards Optomed’s current share price levels as an attractive long-term entry point, following its case review (prompted by a change in analysts). We apply a new Base Case of EUR 9 (13).

Muut analyysit
4.8.
2022

Redeye provides its comments on Optomed’s Q2’22 report. We note that Optomed had lower sales than last year’s second quarter but that the company believes in a stronger second half of the year.

Muut analyysit
6.5.
2022

Redeye maintains its valuation of Optomed after the Q1 report.

Muut analyysit
18.2.
2022

Redeye maintains its positive view and valuation of Optomed. The company refocuses its sales efforts from the Eastern markets to the USA and Western Europe.

Muut analyysit
8.2.
2022

Redeye believes there is a high likelihood Optomed will receive an approval by the FDA for the marketing of the autonomous AI for more than mild diabetic retinopathy - based on the presented clinical trial results with Aurora AEYE.

Muut analyysit
14.7.
2021

Redeye revises slightly its revenue and EBITDA projections for 2021. While we remain conservative in our near-term expectations, we maintain our conviction that Optomed is on the path of spectacular growth.

Muut analyysit
11.5.
2021

Redeye sees one more sign for sales growth for Optomed with the market authorization for the Aurora camera in Brazil.

Muut analyysit
6.5.
2021

Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.

Muut analyysit
12.4.
2021

Redeye raises the fair value of Optomed to EUR 13 per share, a new bull case of EUR 17 per share and a bear case of EUR 5. As we expected, the trend for "remote-everything" favours Optomed. We believe this transformation will continue and even accelerate in the coming years and see Optomed as positioned for strong growth with both superior technology and solid execution capability.

Optomed

ipo 

Inderes kategoriat

Inderes Yhtiöasiakas